Decision analytic modelling is a widely used method for economic analysis that enables integration of all relevant evidence and facilitates comparative analysis of multiple intervention strategies over long period of time. In this theme, we work towards development of the methods of decision analytic modelling and develop models to support rigorous evaluations in collaboration with clinicians, patients and other stakeholders. We also teach decision analytic modelling methods in our courses.

Specific topics of our work include:

• Decision modelling for long-term economic analysis in clinical trials
• Decision modelling for assessment of public health interventions
• Decision modelling to support personalised medicine
• Validation and calibration of decision models

Ongoing projects

CVD

• CTT
• East London CVD prevention

Respiratory

• CHILL

Surgery

• OSIRIS

Neurology

• MS: CHARIOT-MS
• Point of care antibody testing

Nutrition

• Fresh St

UK Salt reformulation policy

References to our published papers:

Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor G, He F, Mihaylova B (2021). Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England. Hypertension. 77( 4): 1086-1094.

Schlackow I, Simons C, Oke J, Feakins B, O'Callaghan CA, Hobbs FDR, Lasserson D, Stevens RJ, Perera R, Mihaylova B (2020). Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. PLoS Med. 17(12):e1003478.

J Oke, B Feakins, I Schlackow, B Mihaylova, C Simons, C O'Callaghan, D Lasserson, R Hobbs, R Stevens, R Perera (2019). Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. F1000Research.

Keng MJ, Tsiachristas A, Leal J, Gray A, Mihaylova B (2019). Impact of variation in Type 2 diabetes care on health and healthcare costs. Diabetes Obesity and Metabolism. 21:2405–2412.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray MJ, Gray A, Baigent C, Mihaylova B, on behalf of the SHARP Collaborative Group (2019). Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease. Kidney International. 96: 170–179.

Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA (2019). Is doctor referral to a low energy total diet replacement programme cost-effective for the routine treatment of obesity?. Obesity. 27: 391-398.

Clayton G, Smith I, Higgins JPT, Mihaylova B, Thorpe B, Cicero R, Lokuge K, Forman J, Tierney JF, White IR, Sharples LD, Jones HE (2017). The INVEST project: Investigating the use of evidence synthesis in the design and analysis of clinical trials. Trials. 18:219.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Wanner C, Fellström B, Gray A, Landray MJ, Baigent C, Mihaylova B on behalf of the SHARP Collaborative Group (2017). A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart.103:1880-1890.

Kent S, Haynes R, Hopewell J, Parish S, Gray A, Landray M J, Collins R, Armitage J, Mihaylova B on behalf of the HPS2-THRIVE Collaborative Group (2016). The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes. 9:348-354.

Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R, Cass A, Craig J, Gray A, Collins R, Landray M, Baigent C (2016). Cost-effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).  American Journal of Kidney Diseases. 67(4): 576-584.

Alva M L, Gray A, Mihaylova B, Leal J, Holman R R (2014). The impact of diabetes-related complications on healthcare costs: new results from the UK Prospective Diabetes Study. Diabetic Medicine. 32(4):459-466.

Mihaylova B, Briggs A, O'Hagan A, Thompson SG (2011). Review of statistical methods for analysing healthcare resources and costs. Health Economics.20(8):897-916.

Mihaylova B, Briggs A, Hlatky M, Armitage J, Parish S, Gray A, and Collins R (2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes. 2:65-72.

Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Roberto F, Remme WJ, Bertrand M, and Fox K (2007). The Cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA Study. Heart. 93: 1081-6.

Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R on behalf of the Heart Protection Study Collaborative Group(2006). Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ;333:1145-8.